CN1546147A - Effervescence tablet for treating children's cough and asthma and its preparation - Google Patents
Effervescence tablet for treating children's cough and asthma and its preparation Download PDFInfo
- Publication number
- CN1546147A CN1546147A CNA2003101191169A CN200310119116A CN1546147A CN 1546147 A CN1546147 A CN 1546147A CN A2003101191169 A CNA2003101191169 A CN A2003101191169A CN 200310119116 A CN200310119116 A CN 200310119116A CN 1546147 A CN1546147 A CN 1546147A
- Authority
- CN
- China
- Prior art keywords
- concentrated
- spent
- night
- filter
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 206010011224 Cough Diseases 0.000 title abstract description 12
- 208000006673 asthma Diseases 0.000 title description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000005469 granulation Methods 0.000 claims abstract description 4
- 230000003179 granulation Effects 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 24
- 208000035756 Infantile asthma Diseases 0.000 claims description 17
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229960004756 ethanol Drugs 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 11
- 239000010231 banlangen Substances 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 238000004321 preservation Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 238000000703 high-speed centrifugation Methods 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- -1 reflux Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 241001465251 Ephedra sinica Species 0.000 abstract 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 8
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010057190 Respiratory tract infections Diseases 0.000 description 5
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 229960002179 ephedrine Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010044302 Tracheitis Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 2
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 2
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960003908 pseudoephedrine Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910000720 Silicomanganese Inorganic materials 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010065899 Tracheal inflammation Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940073569 n-methylephedrine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Abstract
A children's cough relieving effervescent tablet and preparation process, the preparation is prepared from Chinese ephedra, honeysuckle flower, bitter apricot seed, isatic root, gupse, licorice root, and pericarpium trichosanthis through the steps of water grilling, alcohol separating, cold storage, centrifuging, charging Chinese ephedra, extracting concrete, drying and disintegrating, granulation, drying and tabletting.
Description
Technical field: the present invention relates to a kind of Chinese medicine, especially relate to infantile asthma effervescent tablet of a kind of child's of treatment tracheitis, cough, upper respiratory tract infection and preparation method thereof.
Background technology: tracheitis, cough, upper respiratory tract infection are usual diseases of childhood, frequently-occurring disease, also be anxious, the serious symptom of department of pediatrics in clinical, at present, the Chinese medicine of treatment children with tracheal inflammation, cough, upper respiratory tract infection is generally oral liquid, because the extraction process of oral liquid is that simple water is carried, spissated method is prepared from, the finished product precipitation is many, and the loss of effective components of medicine is bigger when refining, affects the treatment, transport in addition, carry equal inconvenience, limited clinical practice.
Summary of the invention: in order to solve the problem of above-mentioned existence, it is good to the invention provides a kind of therapeutic effect, taking convenience, steady quality, and transportation, infantile asthma effervescent tablet easy to carry and preparation method thereof.
Concrete technical scheme is as follows: a kind of infantile asthma effervescent tablet and preparation method thereof is characterized in that: made by weight by following raw materials of effective components:
Herba Ephedrae 0.5-1.5 Flos Lonicerae 5-15 Semen Armeniacae Amarum 1-9
Radix Isatidis 5-15 Gypsum Fibrosum 10-20 Radix Glycyrrhizae 1-9
Fructus Trichosanthis 1-9;
Preparation method:
Above seven flavor medicine, Herba Ephedrae add 6 times of amount 80% ethanol, reflux, extract, 3 times, each 2 hours, filter merging filtrate, placement is spent the night, and filters filtrate recycling ethanol and to be concentrated into 60 ℃ of relative densities when surveying be 1.05-1.06, add the hydrochloric acid solution of 4 times of amounts 0.1% of medicinal liquid while hot, stir well, cold preservation is spent the night, filter, filtrate is regulated pH value near neutral with ammonia, and cold preservation is spent the night, filter filtrate for later use; Other gets Gypsum Fibrosum, after decocting with water half an hour, add Flos Lonicerae again, Semen Armeniacae Amarum, Radix Isatidis, Fructus Trichosanthis, Radix Glycyrrhizae decocts each 1 hour 3 times, amount of water is 10 times of medical material amount, filter, collecting decoction, relative density is 1.05-1.06 when being concentrated into 60 ℃ of surveys, high speed centrifugation under 150000rpm, it is 1.10-1.12 that centrifugal liquid continues to be concentrated into 60 ℃ of relative densities when surveying, and adds ethanol and makes and contain the alcohol amount and reach 65%, and placement is spent the night, filter, filtrate recycling ethanol and to be concentrated into 60 ℃ of relative densities when surveying be 1.03-1.05 adds the water of 3 times of amounts of medicinal liquid, stirs evenly, cold preservation is spent the night, high speed centrifugation under 150000rpm, the extracting solution of centrifugal liquid and above-mentioned Herba Ephedrae merges, and relative density is the thick paste of 1.20-1.25 when continuing to be concentrated into 60 ℃ of surveys, drying under reduced pressure is ground into fine powder; Get above-mentioned dried cream powder, add the tartaric acid of equivalent and the sodium bicarbonate of equivalent, and Aspartane 30 restrains, xylitol is an amount of, mixing is with dehydrated alcohol granulation, dry, tabletting, promptly.
The present invention has carried out independent extraction with the monarch drug Herba Ephedrae, all the other still adopt decocting, collecting decoction is concentrated into the relative density of regulation, precipitate with ethanol, cold preservation, centrifugal, centrifugal liquid is concentrated into behind the thick paste water precipitating again, improving final preparation clarity, be condensed into after centrifugal and add Herba Ephedrae behind the thick paste and extract extractum, be ground into fine powder behind the vacuum drying, make granule with auxiliary materials and mixing again, drying, tabletting promptly, effervescent is dissolved in hot water but the present invention both has, but effervescent is dissolved in the advantage of directly taking behind the cold water again, be suitable for child administration, simultaneously again because it is a solid preparation, transportation, easy to carry, steady quality, increased content of effective after the process modification, improved curative effect, it is big to have overcome former preparation loss of effective components, the finished product precipitation is many, preserves, carry the shortcoming of inconvenience.
Epheday intermedia of the present invention mainly contains alkaloids composition and volatile oil compositions such as ephedrine, pseudoephedrine, ephedine, L-N methylephedrine, d-N-methyl pseudoephedrine, L-demethyl ephedrine, d-demethyl pseudoephedrine; In addition, also contain compositions such as flavonoid, organic acid, catechu matter; Wherein to be that the main effective ingredient of Herba Ephedrae has analgesic, antiinflammatory, the antitussive effect of relievining asthma for alkaloids composition such as ephedrine and volatile oil composition; Because of volatile oil content is low, be difficult to propose, so extraction process is many to consider alkaloid extraction; The extracting method that Herba Ephedrae alkaloid is commonly used has sour water lixiviate, sour water percolation, alcohol reflux, decocting to boil etc., is the quality of each extraction process relatively, with above-mentioned four kinds of main methods Herba Ephedrae has been carried out extracting relatively respectively, sees Table 1:
Different Extraction Method is extracted the ephedrine tables of data
Extracting method | Paste-forming rate (%) | Ephedrine hydrochloride content (mg/g Herba Ephedrae) |
The sour water lixiviate | ????18.77 | ????9.40 |
The sour water percolation | ????15.50 | ????8.22 |
Alcohol reflux | ????16.83 | ????10.25 |
Decocting boils | ????19.33 | ????8.35 |
As shown in Table 2, the highest with the ethanol refluxing process Determination of Ephedrine Hydrochloride, and paste-forming rate is lower.
Other drug:
Flos Lonicerae: main effective ingredient is organic acids such as chlorogenic acid, and water-soluble, Yi Shui carries.
Semen Armeniacae Amarum: mainly contain compositions such as amygdaloside and enzyme, fatty acid, volatile oil, aminoacid; Wherein amygdaloside is the effective ingredient of antitussive and antiasthmatic, and is soluble in water, and suitable decocting extracts.
Gypsum Fibrosum: main component is a hydrous calcium sulfate, still contains Celiang elementses such as titanium, copper, ferrum, aluminum, silicomanganese in addition, and Organic substance, sulfide etc.; The Gypsum Fibrosum decocting liquid causes that to Typhoid Vaccine fever in rabbit has certain antipyretic effect, and tradition is decocted first with Gypsum Fibrosum during clinical practice, reenters other medicines with frying in shallow oil, so should the decocting extraction and be decocted first.
Radix Glycyrrhizae: mainly contain triterpene saponin constituents such as glycyrrhizic acid, enoxolone, and compositions such as flavonoid, alkaloids, polysaccharide, how water-soluble, suitable decocting extracts.
Radix Isatidis: mainly contain indigo, indirubin (but amount is seldom), and some water soluble ingredients.Its decocting liquid has bacteriostasis to staphylococcus aureus, can suppress its proliferation function of the viral infection and the criminal of having system again; So suitable decocting extracts.
Fructus Trichosanthis: mainly contain the triterpene saponin constituents, water-soluble, Yi Shui carries.
In sum, above-mentioned 6 flavor medicines should mix decocting and extract, and wherein Gypsum Fibrosum should be decocted first half an hour.
The preparation stability experiment:
It is 75% calorstat that the effervescent tablet of two aluminum laminated films packing is placed 40 ℃, relative humidity, places 1 month, takes out, and measures appearance character, effervescent time and pH value variation before and after its test, the results are shown in Table 2:
Table 1: comparing result before and after the accelerated test
Sample | Appearance character | The effervescent time | PH value |
Before the test | Brown tablet | 5 minutes 15 seconds | 4.1 |
After the test | Brown tablet | 5 minutes 08 second | 4.0 |
The result shows: this medicine has no significant change at aspects such as appearance color, physical behavior, effervescent time and pH values before and after the accelerated test, illustrates that this medicine is basicly stable, and moulding process is reasonable.
Acute toxicity test:
With 3.8 crude drugs/ml concentration, 0.4ml/10g volume gastric infusion, 2 times on the one. accumulated dose is 304g crude drug/kg, is equivalent to 238 times of clinical consumption. observed 7 days, mice all survives, and does not see the overt toxicity reaction.
Long term toxicity test:
Rat is irritated stomach respectively and gives infantile asthma effervescent tablet 94.35,47.175,23.5875g/kg (be equivalent to human dosage 74,27,18.5 times), and continuous 90 days, to observe 14 days after the drug withdrawal, rat all survives, and does not see the overt toxicity reaction.
Antivirus test: the big or middle dosage group of infantile asthma effervescent tablet and oral liquid causes that to the influenza virus infecting mouse pneumonia all has the obvious suppression effect, and the lung exponential quantity obviously reduces.
Bacteriostasis: infantile asthma effervescent tablet and oral liquid all have in various degree inhibitory action to six kinds of antibacterial 19 strain bacterial strains such as examination streptococcus pneumoniae.The heavy dose of group of effervescent tablet can make the golden Portugal of infection bacterium mortality of mice obviously reduce, and the effervescent tablet bacteriostasis is better than oral liquid.
Antitussive action: infantile asthma effervescence tablet and oral liquid all can reduce strong aqua ammonia, citric acid causes mice and guinea pig cough's reaction times and prolongs cough latent period, and prompting has antitussive effect.
Phlegm-dispelling functions: infantile asthma effervescence tablet and oral liquid all can increase phenol red output in the mice trachea, and prompting has certain phlegm-dispelling functions.
Antiinflammatory action: infantile asthma effervescence tablet and oral liquid all can suppress HAC and cause the effect that capillary permeability increases, and prompting has antiinflammatory action.
Refrigeration function: infantile asthma effervescence tablet and oral liquid have tangible refrigeration function to yeast pyrogenicity rat.
The present invention has summed up kinds of Diseases and curative effect and following relation was arranged between the course of treatment through clinical practice, sees Table 3, table 4:
Kinds of Diseases and therapeutic effect relationship
Disease | Case load | Recovery from illness | Remarkable result | Invalid | Effective percentage |
Upper respiratory tract infection | 100 | ?80 | ?20 | ?0 | ?100% |
Acute bronchitis | 80 | ?50 | ?26 | ?4 | ?95% |
Pneumonia | 50 | ?25 | ?23 | ?2 | ?96% |
Cough | 50 | ?27 | ?21 | ?2 | ?96% |
Kinds of Diseases and the course of treatment relation
Disease | Case load | Healing time | |||
One week | Two weeks | Three weeks | All around | ||
Upper respiratory tract infection | 100 | ?20 | ?50 | ?30 | |
Acute bronchitis | 80 | ?5 | ?20 | ?40 | ?11 |
Pneumonia | 50 | ?20 | ?10 | ?18 | |
Cough | 50 | ?20 | ?20 | ?8 |
Usage and consumption:
Two years old with interior one time 1; Three to four years old one time 1.5; Five to seven years old one time 2; 3-4 time on the one, every 1.5g; Be two weeks 1 course of treatment.
Curative effect judging standard:
Recovery from illness: do not have heating, do not have cough, no expectorant, the symptom of relievining asthma;
Produce effects: heating, cough, expectorant, asthma obviously alleviate.
Invalid: as to continue the symptom that heating arranged, cough, have expectorant, asthma.
The specific embodiment:
Embodiment 1: a kind of infantile asthma effervescent tablet and preparation method thereof, make by following raw materials of effective components: (by the gram number)
Herba Ephedrae 62.5g Flos Lonicerae 625g Semen Armeniacae Amarum 312.5g
Radix Isatidis 625g Gypsum Fibrosum 937.5g Radix Glycyrrhizae 312.5g
Fructus Trichosanthis 312.5g;
Preparation method:
Above seven flavor medicine, Herba Ephedrae add 6 times of amount 80% ethanol, reflux, extract, 3 times, each 2 hours, filter merging filtrate, placement is spent the night, and filters filtrate recycling ethanol and to be concentrated into 60 ℃ of relative densities when surveying be 1.05-1.06, add the hydrochloric acid solution of 4 times of amounts 0.1% of medicinal liquid while hot, stir well, cold preservation is spent the night, filter, filtrate is regulated pH value near neutral with ammonia, and cold preservation is spent the night, filter filtrate for later use; Other gets Gypsum Fibrosum, after decocting with water half an hour, add Flos Lonicerae again, Semen Armeniacae Amarum, Radix Isatidis, Fructus Trichosanthis, Radix Glycyrrhizae decocts each 1 hour 3 times, amount of water is 10 times of medical material amount, filter, collecting decoction, relative density is 1.05-1.06 when being concentrated into 60 ℃ of surveys, high speed centrifugation under 150000rpm, it is 1.10-1.12 that centrifugal liquid continues to be concentrated into 60 ℃ of relative densities when surveying, and adds ethanol and makes and contain the alcohol amount and reach 65%, and placement is spent the night, filter, filtrate recycling ethanol and to be concentrated into 60 ℃ of relative densities when surveying be 1.03-1.05 adds the water of 3 times of amounts of medicinal liquid, stirs evenly, cold preservation is spent the night, high speed centrifugation under 150000rpm, the extracting solution of centrifugal liquid and above-mentioned Herba Ephedrae merges, and relative density is the thick paste of 1.20-1.25 when continuing to be concentrated into 60 ℃ of surveys, drying under reduced pressure is ground into fine powder; Get above-mentioned dried cream powder, add the tartaric acid of equivalent and the sodium bicarbonate of equivalent, and Aspartane 30 restrains, xylitol is an amount of, mixing is with dehydrated alcohol granulation, dry, tabletting, promptly.Make 1000 of effervescent tablets altogether.
Embodiment 2: a kind of infantile asthma effervescent tablet and preparation method thereof, make by following raw materials of effective components: (by the gram number)
Herba Ephedrae 62.5g Flos Lonicerae 500g Semen Armeniacae Amarum 250g
Radix Isatidis 562.5g Gypsum Fibrosum 875g Radix Glycyrrhizae 250g
Fructus Trichosanthis 250g;
Preparation method is with embodiment 1.
Embodiment 3: a kind of infantile asthma effervescent tablet and preparation method thereof, make by following raw materials of effective components: (by the gram number)
Herba Ephedrae 62.5g Flos Lonicerae 438g Semen Armeniacae Amarum 188g
Radix Isatidis 438g Gypsum Fibrosum 750g Radix Glycyrrhizae 188g
Fructus Trichosanthis 188g;
Preparation method is with embodiment 1.
Embodiment 4: a kind of infantile asthma effervescent tablet and preparation method thereof, make by following raw materials of effective components: (by the gram number)
Herba Ephedrae 50g Flos Lonicerae 450g Semen Armeniacae Amarum 200g
Radix Isatidis 450g Gypsum Fibrosum 750g Radix Glycyrrhizae 200g
Fructus Trichosanthis 200g;
Preparation method is with embodiment 1.
Embodiment 5: a kind of infantile asthma effervescent tablet and preparation method thereof, make by following raw materials of effective components: (by the gram number)
Herba Ephedrae 40g Flos Lonicerae 320g Semen Armeniacae Amarum 120g
Radix Isatidis 360g Gypsum Fibrosum 400g Radix Glycyrrhizae 120g
Fructus Trichosanthis 120g;
Preparation method is with embodiment 1.
Claims (1)
1, a kind of infantile asthma effervescent tablet is characterized in that: made by weight by following raw materials of effective components:
Herba Ephedrae 0.5-1.5 Flos Lonicerae 5-15 Semen Armeniacae Amarum 1-9
Radix Isatidis 5-15 Gypsum Fibrosum 10-20 Radix Glycyrrhizae 1-9
Fructus Trichosanthis 1-9;
Preparation method:
Above seven flavor medicine, Herba Ephedrae add 6 times of amount 80% ethanol, reflux, extract, 3 times, each 2 hours, filter merging filtrate, placement is spent the night, and filters filtrate recycling ethanol and to be concentrated into 60 ℃ of relative densities when surveying be 1.05-1.06, add the hydrochloric acid solution of 4 times of amounts 0.1% of medicinal liquid while hot, stir well, cold preservation is spent the night, filter, filtrate is regulated pH value near neutral with ammonia, and cold preservation is spent the night, filter filtrate for later use; Other gets Gypsum Fibrosum, after decocting with water half an hour, add Flos Lonicerae again, Semen Armeniacae Amarum, Radix Isatidis, Fructus Trichosanthis, Radix Glycyrrhizae decocts each 1 hour 3 times, amount of water is 10 times of medical material amount, filter, collecting decoction, relative density is 1.05-1.06 when being concentrated into 60 ℃ of surveys, high speed centrifugation under 150000rpm, it is 1.10-1.12 that centrifugal liquid continues to be concentrated into 60 ℃ of relative densities when surveying, and adds ethanol and makes and contain the alcohol amount and reach 65%, and placement is spent the night, filter, filtrate recycling ethanol and to be concentrated into 60 ℃ of relative densities when surveying be 1.03-1.05 adds the water of 3 times of amounts of medicinal liquid, stirs evenly, cold preservation is spent the night, high speed centrifugation under 150000rpm, the extracting solution of centrifugal liquid and above-mentioned Herba Ephedrae merges, and relative density is the thick paste of 1.20-1.25 when continuing to be concentrated into 60 ℃ of surveys, drying under reduced pressure is ground into fine powder; Get above-mentioned dried cream powder, add the tartaric acid of equivalent and the sodium bicarbonate of equivalent, and Aspartane 30 restrains, xylitol is an amount of, mixing is with dehydrated alcohol granulation, dry, tabletting, promptly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310119116 CN1237998C (en) | 2003-12-16 | 2003-12-16 | Effervescence tablet for treating children's cough and asthma and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310119116 CN1237998C (en) | 2003-12-16 | 2003-12-16 | Effervescence tablet for treating children's cough and asthma and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1546147A true CN1546147A (en) | 2004-11-17 |
CN1237998C CN1237998C (en) | 2006-01-25 |
Family
ID=34338142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310119116 Expired - Lifetime CN1237998C (en) | 2003-12-16 | 2003-12-16 | Effervescence tablet for treating children's cough and asthma and its preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1237998C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716246A (en) * | 2012-06-18 | 2012-10-10 | 荣成市商贸城卫生所 | Traditional Chinese medicine composite for treating wind-heat type common cold |
CN107773593A (en) * | 2016-08-30 | 2018-03-09 | 北京盈科瑞创新医药股份有限公司 | A kind of infantile heat-clearing and antitussive Neulized inhalation pharmaceutical solutions and preparation method thereof |
CN111375039A (en) * | 2018-12-29 | 2020-07-07 | 康明 | Traditional Chinese medicine for treating pediatric pneumonia and preparation method thereof |
CN112618612A (en) * | 2021-01-05 | 2021-04-09 | 海南海力制药有限公司 | Traditional Chinese medicine granule for treating infantile cough and asthma and preparation method thereof |
-
2003
- 2003-12-16 CN CN 200310119116 patent/CN1237998C/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716246A (en) * | 2012-06-18 | 2012-10-10 | 荣成市商贸城卫生所 | Traditional Chinese medicine composite for treating wind-heat type common cold |
CN107773593A (en) * | 2016-08-30 | 2018-03-09 | 北京盈科瑞创新医药股份有限公司 | A kind of infantile heat-clearing and antitussive Neulized inhalation pharmaceutical solutions and preparation method thereof |
CN111375039A (en) * | 2018-12-29 | 2020-07-07 | 康明 | Traditional Chinese medicine for treating pediatric pneumonia and preparation method thereof |
CN112618612A (en) * | 2021-01-05 | 2021-04-09 | 海南海力制药有限公司 | Traditional Chinese medicine granule for treating infantile cough and asthma and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1237998C (en) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101049424A (en) | Medication for treating infection in respiratory system | |
US6916494B2 (en) | Anti-hemorrhoid composition and process for its manufacture | |
CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
US7641921B1 (en) | Anti-anal fistula composition and process for its manufacture | |
CN1290544C (en) | Medicine for treating acute and chronic hepatitis | |
WO2011016652A2 (en) | Composition for controlling anal fistulae and method for preparing same | |
CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
CN1073439C (en) | Medicine for treating trachitis and asthma and its preparation | |
CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
CN102949681B (en) | Composition for preventing or treating colds, and its preparation method | |
CN1939499A (en) | Jixiangcao extract, its preparation, medicinal composition and use | |
CN114601807B (en) | Preparation method of fritillaria lung-clearing concentrated pills | |
CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
CN115364169B (en) | Chinese medicinal composition for resisting helicobacter pylori, and preparation method and application thereof | |
CN102429946B (en) | Chinese medicinal composition for preparing anti-influenza virus medicament | |
CN1883654A (en) | Pulse invigorating injection with astragalus root and preparation process thereof | |
CN107412677B (en) | Millettia speciosa tea bag and preparation method thereof | |
CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
CN1403129A (en) | Chinese medicine prepn for stopping drug addiction | |
CN1876075A (en) | A medicine for treating asthma, acute and chronic bronchitis and preparation method thereof | |
CN1259938C (en) | Chinese medicine compound preparation for treating cough and its preparing method | |
CN100335111C (en) | Medicine for rheumatism and its preparation | |
CN1194748C (en) | Medicine for treating hypertension and preparation method | |
CN117530437A (en) | Medicine and food dual purpose composition for preventing and treating alcoholic liver injury and its manufacturing method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: LIAONING AODA PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: YINGKOU AODA PHARMACEUTICAL CO.,LTD |
|
CP01 | Change in the name or title of a patent holder |
Address after: Lunan hi tech Industrial Development Zone, Yingkou, Liaoning, Yingkou Patentee after: LIAONING AODA PHARMACEUTICAL Co.,Ltd. Address before: Lunan hi tech Industrial Development Zone, Yingkou, Liaoning, Yingkou Patentee before: Yingkou Aoda Pharmaceutical Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060125 |